Method development and improvement challenge
Crawford Scientific are offering what they describe as a ?unique new method development service using HPLC columns at the cutting edge of current technology? to customers within the UK.
Crawford Scientific are offering what they describe as a “unique new method development service using HPLC columns at the cutting edge of current technology” to customers within the UK.
Tony Taylor, the company’s technical director comments “We have found, by talking to customers, that new technologies such as sub-2 µm particles, superficially porous silica and HILIC phases can cause technology or knowledge barriers within organizations to seeing what actual improvements and benefits can be realized by implementing these columns.
“We are, therefore, issuing a challenge to customers to submit their existing HPLC method and Crawford will visit the site with a translated method followed by a live demo using a 25% discount column from our current list. In this way there is minimum disruption or cost to the customer and everything to gain.”
Further details are available on-line at www.crawfordscientific.com/method-challenge
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Metabolomics Analysis of Low Birth-Weight Infants Using UHPLC-MS/MS Following Lipid Emulsion
January 10th 2025A recent study aimed to directly compare the changes in serum metabolites among very low birth-rate (VLBW) infants following the administration of the soybean oil-based lipid emulsion and soybean oil, medium-chain triglycerides, olive oil, and fish oil (SMOF) lipid emulsion using untargeted metabolomics techniques.
Analyzing New Drug Modalities: An ISC 2024 Interview with Kelly Zhang
January 10th 2025At ISC 2024 in Liverpool, United Kingdom, LCGC International interviewed Kelly Zhang of Genentech about her work analyzing new drug modalities, such as mRNA, oligonucleotides, peptides, and cell and gene therapies.
